Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAB NASDAQ:CRVO NASDAQ:IPA NASDAQ:MIST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$0.37+1.0%$0.38$0.24▼$2.53$21.38M0.9691,113 shs346,634 shsCRVOCervoMed$10.12-0.7%$7.74$1.80▼$20.63$94.29M-0.79817,438 shs120,318 shsIPAImmunoPrecise Antibodies$2.00-1.0%$1.49$0.27▼$2.41$93.23M0.491.30 million shs767,654 shsMISTMilestone Pharmaceuticals$1.70+1.2%$1.71$0.63▼$2.75$89.82M0.521.01 million shs866,536 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla+0.99%+4.25%-4.49%-8.12%-78.11%CRVOCervoMed-0.69%+2.74%+33.51%+15.26%-40.61%IPAImmunoPrecise Antibodies-0.99%0.00%+3.63%+304.20%+194.12%MISTMilestone Pharmaceuticals+1.19%+13.33%+1.80%+39.34%+19.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCABBioAtla2.3166 of 5 stars3.03.00.00.01.62.50.6CRVOCervoMed2.3564 of 5 stars3.42.00.00.02.41.70.6IPAImmunoPrecise Antibodies2.2748 of 5 stars3.53.00.00.02.50.00.6MISTMilestone Pharmaceuticals1.6108 of 5 stars3.21.00.00.01.72.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCABBioAtla 2.00Hold$5.001,259.80% UpsideCRVOCervoMed 2.78Moderate Buy$21.43111.74% UpsideIPAImmunoPrecise Antibodies 3.00Buy$4.00100.00% UpsideMISTMilestone Pharmaceuticals 2.40Hold$7.00311.76% UpsideCurrent Analyst Ratings BreakdownLatest BCAB, CRVO, MIST, and IPA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025BCABBioAtlaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform8/13/2025BCABBioAtlaCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform8/12/2025CRVOCervoMedRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$20.00 ➝ $16.008/11/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $15.008/11/2025CRVOCervoMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.007/29/2025CRVOCervoMedCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $27.007/25/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/11/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/5/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$5.00(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCABBioAtla$11M1.96N/AN/A($0.29) per share-1.27CRVOCervoMed$9.74M9.61N/AN/A$3.61 per share2.80IPAImmunoPrecise Antibodies$17.59M5.25N/AN/A$0.37 per share5.41MISTMilestone Pharmaceuticals$1M90.88N/AN/A($0.33) per share-5.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCABBioAtla-$69.78M-$1.10N/AN/AN/AN/A-1,177.18%-137.51%N/ACRVOCervoMed-$16.29M-$2.61N/AN/AN/A-290.72%-59.15%-53.64%N/AIPAImmunoPrecise Antibodies-$21.69M-$0.68N/AN/AN/A-122.10%-40.62%-22.19%9/15/2025 (Estimated)MISTMilestone Pharmaceuticals-$41.52M-$0.84N/AN/AN/AN/A-1,672.29%-83.09%N/ALatest BCAB, CRVO, MIST, and IPA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025MISTMilestone Pharmaceuticals-$0.18-$0.20-$0.02-$0.20N/AN/A8/8/2025Q2 2025CRVOCervoMed-$0.57-$0.70-$0.13-$0.70$1.45 million$1.76 million8/7/2025Q2 2025BCABBioAtla-$0.29-$0.31-$0.02-$0.32N/AN/A7/29/2025Q4 2025IPAImmunoPrecise Antibodies-$0.02-$0.04-$0.02-$0.04$7.89 million$5.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCABBioAtlaN/AN/AN/AN/AN/ACRVOCervoMedN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCABBioAtlaN/A1.241.24CRVOCervoMedN/A8.209.78IPAImmunoPrecise Antibodies0.492.081.85MISTMilestone Pharmaceuticals4.064.974.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCABBioAtla77.23%CRVOCervoMed25.15%IPAImmunoPrecise Antibodies6.70%MISTMilestone Pharmaceuticals86.18%Insider OwnershipCompanyInsider OwnershipBCABBioAtla11.22%CRVOCervoMed35.40%IPAImmunoPrecise Antibodies6.83%MISTMilestone Pharmaceuticals19.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCABBioAtla6058.72 million51.86 millionOptionableCRVOCervoMed49.25 million5.98 millionNot OptionableIPAImmunoPrecise Antibodies8046.15 million43.00 millionNot OptionableMISTMilestone Pharmaceuticals3053.46 million43.04 millionOptionableBCAB, CRVO, MIST, and IPA HeadlinesRecent News About These CompaniesMilestone Pharmaceuticals (NASDAQ:MIST) Posts Earnings Results, Misses Expectations By $0.02 EPSAugust 14 at 4:18 PM | marketbeat.comMilestone Pharmaceuticals Advances CARDAMYST with FDA and Financial BoostAugust 13 at 8:28 PM | theglobeandmail.comMilestone Pharmaceuticals reports Q2 EPS (20c), consensus (18c)August 12, 2025 | msn.comMilestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateAugust 12, 2025 | globenewswire.comMilestone Pharmaceuticals (MIST) Expected to Announce Quarterly Earnings on ThursdayAugust 12, 2025 | americanbankingnews.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Sold by Alta Fundamental Advisers LLCAugust 11, 2025 | marketbeat.comAnalysts Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Price Target at $7.00August 8, 2025 | americanbankingnews.comMilestone Pharmaceuticals (MIST) to Release Earnings on ThursdayAugust 7, 2025 | marketbeat.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from BrokeragesAugust 5, 2025 | marketbeat.comShort Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expands By 159.9%August 4, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Kestra Medical Technologies Ltd. (KMTS) and Milestone Pharmaceuticals (MIST)July 18, 2025 | theglobeandmail.comMilestone Pharmaceuticals Remains A Buying Opportunity Despite Recent DilutionJuly 18, 2025 | seekingalpha.comEquities Analysts Set Expectations for MIST Q3 EarningsJuly 17, 2025 | marketbeat.comMilestone Pharmaceuticals Announces Public Offering for $48.7MJuly 16, 2025 | theglobeandmail.comTD Cowen Sticks to Its Hold Rating for Milestone Pharmaceuticals (MIST)July 16, 2025 | theglobeandmail.comHC Wainwright Issues Pessimistic Estimate for MIST EarningsJuly 16, 2025 | marketbeat.comUS FDA accepts for review Milestone Pharma’s response to CRL for Cardamyst nasal sprayJuly 14, 2025 | pharmabiz.comPMilestone Pharmaceuticals Inc. (MIST) Stock Price Today - WSJJuly 11, 2025 | wsj.comMilestone says heart disorder therapy under FDA review againJuly 11, 2025 | msn.comMilestone Pharmaceuticals stock plunges on public offering announcementJuly 11, 2025 | au.investing.comMilestone Pharmaceuticals Shares Drop Sharply After Public Offering AnnouncementJuly 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 20253 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025CrowdStrike Stock Eyes Next Move With AI in FocusBy Chris Markoch | July 29, 2025Zebra Technologies: Riding the Automation Wave to ProfitsBy Thomas Hughes | August 5, 2025BCAB, CRVO, MIST, and IPA Company DescriptionsBioAtla NASDAQ:BCAB$0.37 +0.00 (+0.99%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$0.38 +0.01 (+2.26%) As of 08/15/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.CervoMed NASDAQ:CRVO$10.12 -0.07 (-0.69%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$10.00 -0.12 (-1.15%) As of 08/15/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.ImmunoPrecise Antibodies NASDAQ:IPA$2.00 -0.02 (-0.99%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$2.02 +0.02 (+1.00%) As of 08/15/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Milestone Pharmaceuticals NASDAQ:MIST$1.70 +0.02 (+1.19%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.68 -0.01 (-0.88%) As of 08/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Arista Networks: Cashing In as the Tollbooth for AI Traffic Green Dot's 30% Rally: Turnaround Takes Off on Explosive Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access